Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. [electronic resource]
Producer: 20200806Description: 506-508 p. digitalISSN:- 2152-2669
- Adolescent
- Adult
- Cohort Studies
- Combined Modality Therapy
- Feasibility Studies
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation -- mortality
- Humans
- Leukemia, Myeloid, Acute -- drug therapy
- Maintenance Chemotherapy
- Male
- Middle Aged
- Mutation
- Prognosis
- Protein Kinase Inhibitors -- therapeutic use
- Remission Induction
- Sorafenib -- therapeutic use
- Survival Rate
- Transplantation, Homologous
- Young Adult
- fms-Like Tyrosine Kinase 3 -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.